Reporting on Adverse Clinical Events, 2018

DOI: 10.1177/0069477018812815

Keywords: Antibiotics (291),Antidiabetics (303),Antihyperlipidemics (303),Antihypertensives (303),Attention-Deficit/Hyperactivity,Disorder Medications (302),Dabrafenib (298),Dietary Supplement (292),Dronabinol (294),Fluoroquinolones (297),Ifosfamide (295),Immunoglobulin, Intravenous (296),Isoniazid (293),Lurasidone (301),Methadone (299),Norfloxacin (293),Ofloxacin (293),Rivoraxaban (300),Salicylic Acid, Topical (290),Trametinib (298),Trazodone (299)

Full-Text